As regards drug injury lawsuits concerning the melanoma side effect of male erectile dysfunction (ED) pills, that litigation began with Viagra cases being filed against Pfizer, the drug company responsible for Viagra. By April 2016 there was a sufficient federal court Viagra lawsuits filed that the Judicial Panel on Multidistrict Litigation (JPML) … [Read more...]
Mesothelioma Treatment Center at Baylor St. Luke’s launches clinical trial for cancer patients
The Baylor College of Medicine Mesothelioma Treatment Center at Baylor St. Luke’s Medical Center announced today that it has opened a new clinical trial that combines immunotherapy and surgery for the treatment of mesothelioma. This is the first in-human study of neoadjuvant (before surgery) administration of a checkpoint inhibitor immunotherapy … [Read more...]
Risk of Hepatitis B Reactivation Associated With Gleevec And Iclusig
Currently available medicines in the BCR-ABL TKIs class of drugs include Gleevec and Iclusig, as well as Tasigna, Bosulif, and Sprycel. These BCR-ABL tyrosine kinase inhibitors (TKIs) are used for the treatment of specific types of blood cancers, including Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) and Ph+ acute … [Read more...]
Mesothelioma from asbestos exposures: Epidemiologic patterns and impact in the United States
Mesothelioma, a rare tumor, is highly correlated with asbestos exposure. Mesothelioma, similar to all asbestos-related diseases, is dose/intensity dependent to some degree, and studies showed the risk of mesothelioma rises with cumulative exposures. Multiple processes occur in an individual before mesothelioma occurs. The impact of mesothelioma in … [Read more...]
Black-Box Warning For Harvoni, Sovaldi, Viekira Pak: Hepatitis B Risk
Direct-acting antivirals (DAAs) are a class of prescription medicines that are FDA-approved to treat adults with hepatitis C virus (HCV) infection. These medicines are available as single-ingredient products and also in combination with other HCV medicines. Here is a list of direct-acting antivirals currently available in the US: Daklinza … [Read more...]
COA finds electrician can sue former employers for mesothelioma diagnosis
The Indiana Court of Appeals held Wednesday that an electrician can sue his former employers for negligence and liability after he was exposed to asbestos. Larry Myers worked as an electrician for Koontz-Wagner Electric from 1961 to 1980, serving as an independent contract for companies such as Bremen Casting and Mastic Home Exteriors Inc. During … [Read more...]
What’s in a Name? Debate on What to Call Novel Oral Anticoagulants
Recently, controversy has arisen over what to call the novel oral anticoagulant class of drugs, which includes Pradaxa, Xarelto, Savaysa, and Eliquis. The article "NOAC, DOAC, or TSOAC: What Should We Call Novel Oral Anticoagulants?" provides some interesting information about the different sides of this debate. Here is a list of the possible … [Read more...]
September 2016 Savaysa Label Change Points Out There Is Still No Antidote
Savaysa (edoxaban) is a factor Xa inhibitor which was approved by the FDA in 2015. Savaysa has the following so-called “indications” or approved uses: To reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation; and, For the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following … [Read more...]
Adjuvant Chemotherapy Improves Survival in Diffuse Malignant Peritoneal Mesothelioma
This retrospective study evaluated the effects of perioperative treatment options in 126 patients with diffuse malignant peritoneal mesothelioma (DMPM) undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC). The 5-year overall survival was significantly different among the perioperative treatment groups: 40% in … [Read more...]
FDA grants fast track designation to galinpepimut-S for malignant plural mesothelioma
The FDA granted fast track designation to galinpepimut-S for the treatment of malignant pleural mesothelioma, according to the drug’s manufacturer. “This fast track designation underscores the importance of galinpepimut-S as a potential treatment option in mesothelioma … [We] expect the fast track designation to expedite the time to market, … [Read more...]
- « Previous Page
- 1
- …
- 62
- 63
- 64
- 65
- 66
- 67
- Next Page »